BPC-157 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Leaf protein concentrate (LPC) is a proteinaceous edible mass extracted from leaves. It can be a lucrative source of low-cost and sustainable protein for food as well as feed applications. Although the proteinaceous extracts from leaves have been described as early as 1773 by Rouelle, large scale extraction and production of LPC was pioneered post the World War II. In fact, many innovations and advances made with regards to LPC production occurred in parallel to the Green Revolution. In some respects, these two technologies were complimentary in that the Green Revolution sought to increase agrarian productivity through increased crop yields via fertiliser use, mechanisation and genetically modified crops, while LPC offered the means to better utilise available agrarian resources through efficient protein extraction.
where "ads" stands for "adsorbed", "m" stands for "monolayer equivalence" and "vap" is reference to the vapor pressure of the liquid adsorptive at the same temperature as the solid sample. The unit function creates the definition of the molar energy of adsorption for the first adsorbed molecule by:
=== Second Trump administration (2025–present) === In January 2025, President Donald Trump revoked Biden's Executive Order 14110 (Executive Order on Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence) by issuing Executive Order 14148 (Initial Rescissions of Harmful Executive Orders and Actions), reflecting his administration's preference for deregulating AI in support of innovation over safeguarding risks. He then issued Executive Order 14179 (Removing Barriers to American Leadership in Artificial Intelligence), which called for development of a national "AI Action Plan" and aimed to strengthen U.S. leadership in AI. In 2025, Congress passed legislation targeting AI-generated deepfakes, the TAKE IT DOWN Act, which prohibits nonconsensual disclosure of AI-generated "intimate imagery", requiring all platforms to remove such content. Lawmakers also reintroduced the CREATE AI Act to codify the National AI Research Resource (NAIRR), which aimed to expand public access to computing resources, datasets, and AI testing environments. Meanwhile, the Department of Commerce also expanded export controls on AI technology, and NIST published an updated set of guidances on AI cybersecurity risks. In March 2025, OpenAI made a policy proposal for the Trump administration to preempt pending AI-related state laws with federal laws. Meta, Google, IBM and Andreessen Horowitz also pressured the government to adopt national rules that would rein in state laws, especially in California.
Cytometry by time of flight, or CyTOF, is an application of mass cytometry used to quantify labeled targets on the surface and interior of single cells. CyTOF allows the quantification of multiple cellular components simultaneously using an ICP-MS detector. CyTOF takes advantage of immunolabeling to quantify proteins, carbohydrates or lipids in a cell. Targets are selected to answer a specific research question and are labeled with lanthanide metal tagged antibodies. Labeled cells are nebulized and mixed with heated argon gas to dry the cell containing particles. The sample-gas mixture is focused and ignited with an argon plasma torch. This breaks the cells into their individual atoms and creates an ion cloud. Abundant low weight ions generated from environmental air and biological molecules are removed using a quadrupole mass analyzer. The remaining heavy ions from the antibody tags are quantified by Time-of-flight mass spectrometry. Ion abundances correlate with the amount of target per cell and can be used to infer cellular qualities. Mass spectrometry's sensitivity to detect different ions allows measurements of upwards of 50 targets per cell while avoiding issues with spectral overlap seen when using fluorescent probes. However, this sensitivity also means trace heavy metal contamination is a concern. Using large numbers of probes creates new problems in analyzing the high dimensional data generated.
Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour. Common side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended. Famotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2023, it was the 33rd most commonly prescribed medication in the United States, with more than 16 million prescriptions.
Sources: en.wikipedia.org
James Orsen Bakker (; born January 2, 1940) is an American televangelist. Between 1974 and 1987, Bakker hosted the television program The PTL Club and its cable television platform, the PTL Satellite Network, with his then wife, Tammy Faye. He also developed Heritage USA, a now-defunct Christian theme park in Fort Mill, South Carolina. Bakker was born in Muskegon, Michigan, and attended North Central University in Minneapolis, where he met Tammy Faye LaValley. The two married in 1961, left college, and became itinerant evangelists, eventually having two children. In the late 1980s, Bakker resigned from the PTL ministry over a cover-up of hush money to church secretary Jessica Hahn for an alleged rape. Subsequent revelations of accounting fraud brought about felony charges, conviction, imprisonment. Convicted of fraud and conspiracy in 1989, he served nearly five years in prison before being paroled in 1994. Bakker later remarried and returned to televangelism, founding Morningside Church in Blue Eye, Missouri, and reestablishing the PTL ministry. After being divorced by Tammy Faye in 1992, Bakker married Lori Beth Graham in 1998, and together they adopted five children. Early in his career, Bakker worked at Pat Robertson’s Christian Broadcasting Network, helping to grow the network and hosting shows including The 700 Club and a children’s program.
Fission cross sections are a measurable property related to the probability that fission will occur in a nuclear reaction. Cross sections are a function of incident neutron energy, and those for 235U and 239Pu are a million times higher than 238U at lower neutron energy levels. Absorption of any neutron makes available to the nucleus binding energy of about 5.3 MeV. 238U needs a fast neutron to supply the additional 1 MeV needed to cross the critical energy barrier for fission. In the case of 235U however, that extra energy is provided when 235U adjusts from an odd to an even mass. In the words of Younes and Lovelace, "...the neutron absorption on a 235U target forms a 236U nucleus with excitation energy greater than the critical fission energy, whereas in the case of n + 238U, the resulting 239U nucleus has an excitation energy below the critical fission energy." About 6 MeV of the fission-input energy is supplied by the simple binding of an extra neutron to the heavy nucleus via the strong force; however, in many fissionable isotopes, this amount of energy is not enough for fission. Uranium-238, for example, has a near-zero fission cross section for neutrons of less than 1 MeV energy. If no additional energy is supplied by any other mechanism, the nucleus will not fission, but will merely absorb the neutron, as happens when 238U absorbs slow and even some fraction of fast neutrons, to become 239U.
=== No development reported === 4-Chlorokynurenine (4-CL-KYN; 7-CL-KYNA; AV-101) – ionotropic glutamate NMDA receptor antagonist and 3-hydroxyanthranilate oxidase inhibitor [146] α-Synuclein picobody (a-syn-pico) – positron-emission tomography (PET) enhancer – diagnosis [147] A-86929 – dopamine D1 receptor agonist [148] AB-4166 – microbiome modulator [149] ACI-12589 – positron-emission tomography (PET) enhancer – diagnosis [150] Affitope-PD03 (PD03; PD03A) – α-synuclein inhibitor and immunostimulant [151] ANPD-002 (ANPD002) – dopaminergic cell replacement [152] AP-472 – metabotropic glutamate mGlu4 receptor positive allosteric modulator [153] Aplindore (DAB-452; palindore; SLS-006; WAY-DAB 452) – dopamine D2 receptor agonist [154] Armesocarb (MLR-1019) – atypical dopamine reuptake inhibitor (DRI) [155] Atuzaginstat (COR-388) – peptide hydrolase inhibitor [156] ATV:aSyn (ATV:α-synuclein; ATV:αSyn) – α-synuclein inhibitor [157] Autologous adipose derived mesenchymal stem cells - Hope Biosciences – cell replacement [158] AZ-001 – undefined mechanism of action [159] Beperminogene perplasmid (AMG-0001; Collategene; hepatocyte growth factor gene therapy) – gene transference and hepatocyte growth factor (HGF) expression stimulant [160] BTRX-246040 (LY-2940094) – nociceptin receptor (NOP) antagonist [161] Cannabidiol/tetrahydrocannabinol (CBD/THC; CanChew; MedChew; THC/CBD) – cannabinoid CB1 and CB2 receptor agonist and other actions [162] Carbidopa/levodopa (WD-1603) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [163] Carbidopa/levodopa oral solution (EXN-32) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [164] Ciforadenant (CPI-444, V-81444) – adenosine A2A receptor antagonist CM-4612 (CM-ADHD; CM-AT; CM-PK) – enzyme replacement and modulator [165] Crisdesalazine (AAD-2004) – microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor [166] CTx-GBA1 – gene transference [167] Cu(II)ATSM (copper(II)-ATSM; Cu-ATSM) – neuron modulator [168] Debamestrocel (autologous bone marrow derived mesenchymal stem cell therapy; NurOwn) – dopaminergic cell replacement [169] DNL-201 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [170] Dopamine intranasal – non-selective dopamine receptor agonist [171] DX-0308 (DX-308) – retinoic acid metabolism modulator [172] Emrusolmin (anle-138b; TEV-56286) – α-synuclein inhibitor and protein aggregation inhibitor [173] ESB-1609 – sphingosine-1-phosphate (S1P) receptor agonist [174] ESB-5070 – leucine-rich repeat kinase 2 (LRRK2) inhibitor [175] F-14413 – α2-adrenergic receptor inverse agonist [176] FB-101 (1ST-102) – Bcr-Abl tyrosine kinase inhibitor [177] Fibroblast growth factor 1 (FGF-1) – fibroblast growth factor stimulant and angiogenesis-inducing agent [178] GO-101 – gene transference [179] GT-02329 – β-glucocerebrosidase (GCase) activator and/or chaperone [180] ISC-hpNSC (human parthenogenetic neural stem cells) – dopaminergic cell replacement [181] Itanapraced (CHF-5074; CSP-1103) – γ-secretase modulator and non-steroidal anti-inflammatory drug (NSAID) derivative lacking cyclooxygenase (COX) inhibition [182] Levodopa deuterated (deuterium-containing levodopa; SD-1077) – dopamine precursor and indirect non-selective dopamine receptor agonist [183] Liatermin (BVF-014; GDNF; glial-derived neutrotrophic factor; r-metHuGDNF) – neuron stimulant [184] Lu-AE-04621 (Lu-AE04621) – dopamine receptor agonist (prodrug of Lu-AA40326) [185] Masupirdine (SUVN-502; SUVN502) – serotonin 5-HT6 receptor antagonist [186] Mesocarb (MLR-1017) – atypical dopamine reuptake inhibitor (DRI) [187] MTK-458 – protein-serine-threonine kinase stimulant [188] NPT-200-11 (NPT200-11; UCB-1332) – α-synuclein inhibitor [189] NPT-520-34 (NPT520-34) – 1-phosphatidylinositol 3 kinase modulator and other actions [190] ODM-104 – catechol O-methyltransferase (COMT) inhibitor [191] OP-101 (dendrimer N-acetylcysteine) – various actions [192] OP-501 – catechol O-methyltransferase (COMT) inhibitor [193] Ordopidine (ACR-325) – low-affinity dopamine D2 receptor antagonist and dopaminergic stabilizer [194] PD-04 (a-Syn-PD-04; Affitope PD-04; PD04) – peptide vaccine against α-synuclein [195] Rasagiline – monoamine oxidase B (MAO-B) inhibitor [196] Rasagiline transdermal patch (TPU-002RA) – monoamine oxidase B (MAO-B) inhibitor [197] Research programme: adenosine A2A/A1 selective antagonists - Domain Therapeutics/CleveXel Pharma (CVXL-0069; DT-1133; DT0926; FP-0692; FP-1133) – adenosine A1 receptor antagonists and adenosine A2A receptor antagonists [198] Research programme: catalytic antioxidants - Aeolus Pharmaceuticals (AEOL-10113; AEOL-11207) – antioxidants [199] Research programme: central nervous system therapeutics - Delpor – undefined mechanism of action [200] Research programme: cGAS/STING antagonists - IFM Due – nucleotidyltransferase inhibitors [201] Research programme: COMT inhibitors - Avalo Therapeutics (AVTX-406; CERC-425; CERC-406) – catechol O-methyltransferase (COMT) inhibitors [202] Research programme: dopamine D1 receptor agonists - Takeda – dopamine D1 receptor agonists [203] Research programme: exosome therapeutics - ArunA Biomedical – undefined mechanism of action [204] Research programme: GPCR modulators - Nxera Pharma – various actions [205] Research programme: KEAP1 inhibitors - Keapstone Therapeutics – Kelch-like ECH-associated protein 1 (KEAP1) inhibitors [206] Research programme: long-acting neuropsychiatric therapeutics - Teva (NP-201; NP-202; risperidone/ropinirole implants) – various actions [207] Research programme: LRRK2 inhibitor - GlaxoSmithKline – leucine-rich repeat kinase 2 (LRRK2) inhibitors [208] Research programme: LRRK2 inhibitors - Novartis – leucine-rich repeat kinase 2 (LRRK2) inhibitors [209] Research programme: neurodegenerative disorder gene therapies - Denali Therapeutics (AAV-LF2; CNS-directed AAV-based gene therapies) – gene transference [210] Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience (AD-0802; AD-1502; AD-2203; AE-1501; BAN-2203; BAN-2502; BAN2401 back-up) – various actions [211] Research programme: neurodegenerative disorder therapeutics - Celgene Corporation/Evotec (BMSxxx) – cell replacements [212] Research programme: neurodegenerative disease therapeutics - ProteoTech (DP-68; DP-74; PD-61-W3; PeptiClere; PTI-19; PTI-51; PTI-51-CH3; Synuclere; TauPro) – various actions [213] Research programme: neurological disorders therapeutics - Gloriana therapeutics (ECB-PD; ECT-PD; Meteorin; Ns-G34; NsG-0301; NsG-33) – glial cell line-derived neurotrophic factor modulators [214] Research programme: Parkinson's disease therapeutics - Alectos Therapeutics – glucocerebrosidase 2 (GBA2) protein inhibitor [215] Research programme: Parkinson's disease therapies - Zymes (co-Q10; coenzyme Q10; ubidecarenone) – antioxidants [216] Research programme: Parkinson's disease therapy - AbbVie – dopamine D2 and D3 receptor agonists [217] Research programme: positive allosteric modulators - Proximagen – various actions [218] Research programme: protective autoimmunity enhancer - Proneuron Biotechnologies (PN-277) – immunomodulators [219] Research programme: protein phosphatase 2A modulators - Signum Biosciences (SIG-1012; SIG-1106) – protein phosphatase 2A (PP2A) modulator [220] Research programme: small molecule therapeutics - Amathus Therapeutics – mitochondrial protein stimulants [221] Research programme: small molecule therapeutics - Aranda Pharma/Tarrex Biopharma (ADA-308; ADA-409; Backup; MDA-308; MDA-409) – androgen receptor antagonists [222] Research programme: transmembrane protein 175 agonists - AbbVie/Caraway Therapeutics – TMEM175 stimulants [223] Rotigotine controlled release (SER-214) – non-selective dopamine receptor agonist and other actions [224] S-32504 – dopamine D2 and D3 receptor agonist [225] SAGE-324 (BIIB-124) – GABAA receptor positive allosteric modulator and neurosteroid [226] Saracatinib (AZD-0530) – Src-family kinase inhibitor [227] Selegiline transdermal (Emsam) – monoamine oxidase B (MAO-B) inhibitor and other actions [228] Seridopidine (ACR343; ACR-343) – dopamine receptor modulator and so-called "dopaminergic stabilizer" [229] SLS-004 (LV-dCas9-DNMT3A) – gene therapy and α-synuclein expression inhibitor [230] Sonlicromanol (KH-176) – prostaglandin-E synthase inhibitor and reactive oxygen species modulator [231] SPN-803 (SPN803) – undefined mechanism of action [232] STEL-101 (AMA-101; STL-101) – undefined mechanism of action [233] UB-312 – immunostimulant [234] YKP-10461 (SKL-PD; YKP10461) – monoamine oxidase B (MAO-B) inhibitor [235] YTX-7739 – stearoyl-CoA desaturase inhibitor [236] Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist [237]
=== Human health === The effect of rBGH on human health is an ongoing debate, in part due to the lack of conclusive evidence. A few of the most debated issues include: Insulin-like growth factor 1 (IGF-1) is a hormone found in humans that is responsible for growth promotion, protein synthesis, and insulin actions over the lifecycle. The hormone has been shown to influence the growth of tumors in some studies and may be linked to the development of prostate, colorectal, breast, and other cancers. IGF-1 is also found in milk. Previous research has proposed an increase of IGF-1 in rBST-treated cows, but this claim is currently not substantiated. In addition, no current evidence shows that orally consumed IGF-1 is absorbed in humans and the dietary amount is negligible when compared to what the body produces on its own. "IGF-1 in milk is not denatured (inactivated) by pasteurization. The extent to which intact, active IGF-1 is absorbed through the human digestive tract remains uncertain." The American Cancer Society has reviewed the evidence concerning IGF-1 in milk from rBST-treated cows, and found that: "While there may be a link between IGF-1 blood levels and cancer, the exact nature of this link remains unclear. Some studies have shown that adults who drink milk have about 10% higher levels of IGF-1 in their blood than those who drink little or no milk. But this same finding has also been reported in people who drink soy milk.
On its return, one of the first acts of the government was to establish new ranks for the nobility. Five hundred people from the old court nobility, former daimyo, and samurai who had provided valuable service to the Emperor were organized into a new peerage, the Kazoku, consisting of five ranks: prince, marquis, count, viscount, and baron. In the transition between the Edo period and the Meiji era, the Ee ja nai ka movement, a spontaneous outbreak of ecstatic behavior, took place. In 1885, noted public intellectual Yukichi Fukuzawa wrote the influential essay "Leaving Asia", arguing that Japan should orient itself in the image of the "civilized countries of the West", leaving behind the "hopelessly backwards", "oriental barbaric" Asian neighbors, namely Joseon Korea and Qing China. This essay certainly encouraged the economic and technological rise of Japan in the Meiji era, but it also may have laid the intellectual foundations for later Japanese colonialism in the region.
Sources: en.wikipedia.org
RA reduces the size and secretion of the sebaceous glands, and by doing so reduces bacterial numbers in both the ducts and skin surface. It reduces inflammation via inhibition of chemotactic responses of monocytes and neutrophils.
Often, when British allies attempted military actions within several dozen miles or so of the sea, the Royal Navy would arrive, land troops and supplies, and aid the coalition's land forces in a concerted operation. Royal Navy ships even provided artillery support against French units when fighting strayed near enough to the coastline. The ability and quality of the land forces governed these operations. For example, when operating with inexperienced guerrilla forces in Spain, the Royal Navy sometimes failed to achieve its objectives because of the lack of manpower that the Navy's guerrilla allies had promised to supply.
Lysyl oxidase the terminal carbon of the side chain of lysyl residue side chain. The enzyme belongsthe category of quinone-containing copper amine oxidases. The reaction requires the cofactor lysyl tyrosylquinone (LTQ). The LTQ cofactor is unique among quinones because it contains an 1,2-benzoquinone substituent. Furthermore, it is neutral charge at physiological pH. The ε-amine is condenses with LTQ to give the Schiff base via reaction with LTQ. The rate-limiting removal of a ε-proton yields an imine. Subsequent hydrolysis of the imine leads to release of the allysine residue. Molecular oxygen and the copper ion are utilized to reoxidize the cofactor, producing hydrogen peroxide as a side product.
== See also == Trade Incense trade route, a large network around the Mediterranean and beyond Land of Frankincense (Frankincense Trail), site in Oman Nabataeans, a trader tribe Literature Desi Sangye Gyatso, author of a Tibetan herbal Historia Plantarum (Theophrastus book) Similar plants and products Agarwood Benzoin (resin) Copal Elemi, resin or tree Myrrh, resin Palo santo (Bursera graveolens), tree Pistacia lentiscus (mastic tree), and Mastic (plant resin)
== Conjunctival immune response == The conjunctiva covers the sclera, or whites of the eyes, as well as the insides of the eyelids and provides nutrients to underlying and surrounding tissue. The conjunctiva is also one of the closest vascularized tissues to the cornea. As such, it provides a major source of immune components in the cornea. Not only does the conjunctiva produce IgA, like the lacrimal glands, but it also contains macrophages, neutrophilic granulocytes, mast cells, lymphocytes, and other aspects of the general mucosal immune system. Like the rest of the MALT pathway, the conjunctiva has been found to possess lymphoid follicles, which develop at puberty and decline in old age, as well as diffuse lymphoid tissues. The conjunctiva also possess macrophages that play a part in modulating the T-cell immune response and mediating both the innate and acquired immune responses.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.